ITOS
ITeos Therapeutics Inc

519
Loading...
Loading...
News
all
press releases
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
Zacks·3mo ago
News Placeholder
More News
News Placeholder
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’
The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended.
Stocktwits·3mo ago
News Placeholder
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
Zacks·4mo ago
News Placeholder
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish
The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.
Stocktwits·4mo ago
News Placeholder
iTeos Therapeutics presents preclinical data on EOS-984
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...
Globe Newswire·1y ago
News Placeholder
iTeos Therapeutics (ITOS, $13.35) RSI Indicator left the overbought zone on April 01, 2024
This is a signal that ITOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Increase in Short Interest
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an...
Zolmax·1y ago
News Placeholder
iTeos Therapeutics (ITOS, $13.19) RSI Indicator left the overbought zone on March 27, 2024
This is a signal that ITOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
iTeos Therapeutics (ITOS, $10.81) entered Downtrend as Momentum indicator drops below 0 level on Mar 15, 2024
This indicator may be signaling that ITOS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·1y ago

Latest ITOS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.